Scott Fidel

Q: What is Scott Fidel's success rate?

Scott Fidel currently has a success rate of 94.66091125914645.

Q: What is the average return of Scott Fidel's calls?

Their stock ratings have generated an average return of 32.40175844004354.

Goldman Sachs | Healthcare

Scott Fidel is an analyst from Goldman Sachs specializing in the Healthcare sector. Ranked #817 out of 4773 analysts, they have issued 28 stock ratings with a success rate of 94.66% and an average return of 32.40%.

Scott Fidel has a well-established track record, with 28 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 94.66% and an average return of 32.40%, underscoring their expertise and ability to identify winning opportunities for investors.

#817

Out of 4773

Total Ratings

+94.66%

Success Rate

+32.40%

Average Return

Recent Ratings Analysis

UHS

Hold

Jul 30, 2026

Target

$190.00

Current

$174.83

Performance

7.07%

Scott Fidel rated UHS as Neutral on Jul 30, 2026, setting a price target of 190. Despite the Hold call, shares climbed 7.07% to 174.83, revealing unexpected momentum.

HCA

Buy

Jul 28, 2026

Target

$485.00

Current

$426.94

Performance

2.09%

On Jul 28, 2026, HCA was given a Buy rating by Scott Fidel, with a target price of 485. The stock traded sideways with a 2.09% move, keeping the bullish thesis unresolved.

OPCH

Hold

Jun 08, 2026

Target

$22.00

Current

$23.48

Performance

16.93%

OPCH received a Neutral rating from Scott Fidel on Jun 08, 2026, aiming for 22. Investors saw gains of 16.93% that the cautious stance didn’t fully capture.

GMRS

Buy

Jun 08, 2026

Target

$35.00

Current

$12.78

Performance

20.79%

On Jun 08, 2026, Scott Fidel published a Buy outlook on GMRS, with a target of 35. Shares gained 20.79%, underscoring the accuracy of the bullish outlook toward 35.

BTSG

Buy

Jun 08, 2026

Target

$71.00

Current

$58.73

Performance

-0.83%

Scott Fidel on Jun 08, 2026 assigned BTSG a Buy rating, with a price target of 71. The recommendation remains pending validation as shares consolidate around 58.73.

CON

Buy

Jun 05, 2026

Target

$30.00

Current

$34.95

Performance

38.03%

On Jun 05, 2026, Scott Fidel reaffirmed CON with a Buy rating, targeting 30. The recommendation was supported by strong follow-through as the stock rose from 34.95 to 34.95.

LFST

Hold

Jun 05, 2026

Target

$9.00

Current

$12.97

Performance

75.03%

LFST was rated Neutral by Scott Fidel on Jun 05, 2026, with a price objective of 9. Despite caution, upside momentum rewarded risk-takers with gains to 12.97.

AVAH

Buy

May 15, 2026

Target

$11.00

Current

$14.08

Performance

82.38%

On May 15, 2026, Scott Fidel initiated coverage on AVAH with a Overweight rating and target of 11. The stock’s climb of 82.38% since the call highlights the foresight in the rating.

ADUS

Buy

Feb 25, 2026

Target

$140.00

Current

$117.09

Performance

8.82%

Scott Fidel issued a Overweight recommendation for ADUS on Feb 25, 2026, price target set at 140. Investors following the Buy call captured upside momentum, with shares now at 117.09.

MOH

Hold

Feb 12, 2026

Target

$167.00

Current

$204.23

Performance

61.18%

On Feb 12, 2026, MOH was evaluated by Scott Fidel, who gave a Neutral rating and target of 167. Investors who stayed in despite the Hold saw upside of 61.18%.

GRDN

Buy

Jan 14, 2026

Target

$36.00

Current

$43.64

Performance

44.84%

Scott Fidel rated GRDN as Overweight on Jan 14, 2026, setting a price target of 36. The call has proven timely, with shares rising 44.84% toward the price target of 36.

ARDT

Buy

Nov 14, 2025

Target

$17.00

Current

$10.98

Performance

21.86%

On Nov 14, 2025, ARDT was given a Overweight rating by Scott Fidel, with a target price of 17. The stock rallied 21.86% after the rating, narrowing the gap to the target of 17 and validating the bullish stance.

CI

Buy

Nov 04, 2025

Target

$330.00

Current

$280.76

Performance

6.08%

CI received a Buy rating from Scott Fidel on Nov 04, 2025, aiming for 330. Momentum has favored the Buy call, with shares climbing from 280.76 to 280.76, rewarding those who trusted the recommendation.

CNC

Sell

Oct 31, 2025

Target

$38.00

Current

$66.40

Performance

87.73%

On Oct 31, 2025, Scott Fidel published a Sell outlook on CNC, with a target of 38. Investors who followed the Sell rating avoided losses as the stock weakened.

THC

Buy

Oct 14, 2025

Target

$224.00

Current

$263.69

Performance

34.31%

Scott Fidel on Oct 14, 2025 assigned THC a Buy rating, with a price target of 224. The Buy call aligned well with market performance, producing a gain of 34.31%.

OSCR

Hold

Oct 14, 2025

Target

$17.00

Current

$32.77

Performance

58.39%

On Oct 14, 2025, Scott Fidel reaffirmed OSCR with a Neutral rating, targeting 17. Market strength beyond 32.77 went further than the conservative outlook suggested.

ELV

Hold

Oct 14, 2025

Target

$343.00

Current

$418.72

Performance

19.47%

ELV was rated Neutral by Scott Fidel on Oct 14, 2025, with a price objective of 343. Despite caution, upside momentum rewarded risk-takers with gains to 418.72.

ALHC

Buy

Oct 14, 2025

Target

$21.00

Current

$12.61

Performance

-26.94%

On Oct 14, 2025, Scott Fidel initiated coverage on ALHC with a Buy rating and target of 21. The Buy call has yet to be validated as shares remain 8.39 away from the target.

CVS

Buy

Oct 14, 2025

Target

$91.00

Current

$94.66

Performance

18.83%

Scott Fidel issued a Buy recommendation for CVS on Oct 14, 2025, price target set at 91. Investors following the Buy call captured upside momentum, with shares now at 94.66.

UNH

Buy

Oct 14, 2025

Target

$406.00

Current

$379.09

Performance

5.32%

On Oct 14, 2025, UNH was evaluated by Scott Fidel, who gave a Buy rating and target of 406. This case illustrates how a timely bullish rating can translate into tangible gains of 5.32%.

PNTG

Buy

Mar 11, 2025

Target

$38.00

Current

$39.20

Performance

69.04%

Scott Fidel rated PNTG as Overweight on Mar 11, 2025, setting a price target of 38. The call has proven timely, with shares rising 69.04% toward the price target of 38.

AMED

Hold

Mar 04, 2025

Target

$101.00

Current

$100.99

Performance

9.65%

On Mar 04, 2025, AMED was given a Equal-Weight rating by Scott Fidel, with a target price of 101. The stock rallied from 100.99 to 100.99 after the Hold rating, surprising to the upside.

PACS

Buy

Nov 18, 2024

Target

$31.00

Current

$44.76

Performance

164.38%

PACS received a Overweight rating from Scott Fidel on Nov 18, 2024, aiming for 31. Momentum has favored the Buy call, with shares climbing from 44.76 to 44.76, rewarding those who trusted the recommendation.

HUM

Hold

Oct 09, 2024

Target

$250.00

Current

$409.85

Performance

66.98%

On Oct 09, 2024, Scott Fidel published a Equal-Weight outlook on HUM, with a target of 250. The Hold call missed some of the bullish momentum as shares advanced toward 250.

Frequency Asked Questions

Who is Scott Fidel?

Scott Fidel is an analyst from Goldman Sachs specializing in the Healthcare sector.

What is Scott Fidel's success rate?

Scott Fidel currently has a success rate of +94.66%.

How many ratings has Scott Fidel issued?

Scott Fidel has issued 28 stock ratings so far.

What is the average return of Scott Fidel's calls?

Their stock ratings have generated an average return of +32.40%.

What is Scott Fidel's ranking?

Scott Fidel is ranked #817 out of 4773 analysts.

What types of ratings does Scott Fidel give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Scott Fidel?

You can follow Scott Fidel by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Scott Fidel?

Their latest rating was a Hold on UHS issued on 2026-07-30.